As shown in Fig 1E and 1F, patients who had EB1-positive HCC had significantly worse prognosis than those who had EB1-negative, in regard to both cumulative recurrence rate (P < 0.0001) and overall survival rate (P < 0.0001; the median survival times of patients with EB1-positive and negative HCC were 16.5 and 3.9 years, respectively). The gene discussed is MAPRE1; the disease is hepatocellular carcinoma.